Correlation Between Immunovant and Apellis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Immunovant and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immunovant and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Immunovant and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Immunovant and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immunovant with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immunovant and Apellis Pharmaceuticals.

Diversification Opportunities for Immunovant and Apellis Pharmaceuticals

0.42

Correlation Coefficient

Immunovant  Apellis Pharmaceuticals

Very weak diversification

The 3 months correlation between Immunovant and Apellis is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Immunovant and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Immunovant is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immunovant are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Immunovant i.e., Immunovant and Apellis Pharmaceuticals go up and down completely randomly.

Pair Corralation between Immunovant and Apellis Pharmaceuticals

Given the investment horizon of 90 days Immunovant is expected to under-perform the Apellis Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Immunovant is 1.35 times less risky than Apellis Pharmaceuticals. The stock trades about -0.06 of its potential returns per unit of risk. The Apellis Pharmaceuticals is currently generating about 0.24 of returns per unit of risk over similar time horizon. If you would invest  2,771  in Apellis Pharmaceuticals on August 31, 2024 and sell it today you would earn a total of  643.00  from holding Apellis Pharmaceuticals or generate 23.2% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Immunovant  vs.  Apellis Pharmaceuticals

Immunovant

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Immunovant is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Apellis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Immunovant and Apellis Pharmaceuticals

The main advantage of trading using opposite Immunovant and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immunovant position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.

The idea behind Immunovant and Apellis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.